# Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

> **NCT05303532** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **AstraZeneca** · enrollment: 214 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05303532
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-04-19
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 214 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303532, "Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05303532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*